Viral Infections in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations (VICE)
The objectives of the study are
- to determine the prevalence of respiratory virus infections in COPD patients, during and outside acute exacerbation
- to explore the impact of these viral infections on the outcome of these patients
- to explore the association between blood procalcitonin levels and viral infections in this population.
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Infections
Lung Diseases, Obstructive
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Impact of Viral Infections in Patients With Chronic Obstructive Pulmonary Diseases: Virological Work-up During Exacerbations and 1-year Follow-up|
|Study Start Date:||May 2007|
|Study Completion Date:||September 2009|
|Primary Completion Date:||September 2009 (Final data collection date for primary outcome measure)|
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity due to repeated exacerbations. The impact of viral infections during and outside COPD exacerbations is poorly understood and there is only scarce data on the role of new biological markers of infection for the management of COPD exacerbations.
Objectives of the project
The investigators aim to
- describe the epidemiology of viral infections in patients admitted with an exacerbation of their COPD;
- explore the evolution of viral infections outside exacerbations;
- analyze the impact of viral infections on clinical outcomes;
- explore the role of biological markers (CRP, procalcitonin) for the diagnosis and prognosis of viral infections.
The investigators will prospectively follow-up 100 patients admitted with an acute exacerbation of their COPD. Virological samples will be obtained at admission and at 3 months, to explore the evolution outside episodes of acute exacerbation. Clinical information will be obtained after one-year follow-up. Samples will be tested by RT-PCR for 15 respiratory viruses. The impact of viral infections and the role of biological markers will be explored using univariate and multivariate Cox proportional hazard models.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00448604
|Geneva University Hospital|
|Geneva, Switzerland, 1211|
|Principal Investigator:||Olivier T Rutschmann, MD, MPH||Geneva University Hospital|